QPS opens an additional preclinical research facility in Taiwan
QPS has opened a second preclinical research facility in Taipei, Taiwan. The 2,793-square-foot facility will facilitate a research expansion into additional toxicology studies and a newly launched capability in pharmacology studies.
The new facility became operational in December 2022 and has given QPS significant additional flexibility in study scheduling and additional space to grow the existing toxicology business and build the new pharmacology unit.
This new research facility boasts many well equipped, fully accredited animal centers and a state-of-the-art pharmacology unit. Initially, the center will focus on augmenting the current multi-species capabilities in wound healing models, with pharmacology services in irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH) and atopic dermatitis.
Dr Chen, Deputy General Manager & Head of the Center of Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan commented:
“Preclinical research across various species is a crucial step in the drug development process. Assessing toxicology and safety in these early stages of the research process helps to ensure that new drugs are safe enough to be allowed to progress to First in Human (FIH) clinical research trials”
QPS has hired Mei-Ling Hou to lead the new pharmacology department. Hou joins QPS from the Department of Pharmacology and Toxicology at the Institute for Drug Evaluation Platform, Development Center for Biotechnology (Taipei, Taiwan). Hou’s expertise will hopefully propel the growth and development of this new pharmacology service.
Aligning with the biotech and pharmaceutical industry from preclinical through clinical studies, this new center of excellence will ensure that QPS has the skills, capabilities and space to fully implement global pharma and biotech toxicology and pharmacology drug-related projects.
Source: QPS press release, www.qps.com/press-release/qps-opens-additional-preclinical-research-facility-in-taipei-taiwan/
About QPS Holdings, LLC
QPS is a GLP- and GCP-compliant CRO delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine and clinical development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email [email protected].
QPS contact:
Contact: Gabrielle Pastore, QPS
Email: [email protected]
